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Immunogenicity of Peptides Bound to MHC Class I Molecules 
Depends on the MHC-Peptide Complex  Stability' 
Sjoerd H. van der Burg,* Marjan J. W. Visseren,* Remco M. P. Brandt,* W. Martin Kast,*+ 
and Cornelis J. M. Melief * 
The  impact of the MHC class 1 peptide  binding  stability  on  the  immunogenicity  of  particular  peptide Ags in class  1-restricted 
cytotoxic T lymphocyte  responses is not clearly established.  Therefore,  we  have  determined  the  dissociation rate  of  each  peptide 
from MHC class I at 37°C and  compared  this  to  that of a consensus CTL epitope. Newly defined  immunogenic  peptides  formed 
relatively stable MHC-peptide complexes  as  shown by their low dissociation  rates,  whereas  nonimmunogenic  peptides  displayed 
high  dissociation  rates. In addition  virtually all previously  described HLA-A*0201 -restricted T cell epitopes  showed low disso- 
ciation rates.  Furthermore,  we  show  that  the  immunogenicity of HIV-1-derived peptides  can  be predicted  more  accurately by 
their dissociation rate than by  the MHC class I binding  affinity.  Selection  of  peptides  based  on  atfinity  and  their  dissociation  rate 
leads to a more precise identification  of  candidate CTL epitopes  than  selection  based  on affinity  alone. These results help  to 
understand  why  some  peptides are  recognized  by CTL and,  along with detailed knowledge  of protein processing  rules,  therefore 
have important  implications  for  the  selection of peptides in peptide-based  vaccines.  The journal of Immunology, 1996, 156: 
3308-3314. 
T he protective role of CTL against tumors and viruses has recently been reviewed (1-3). CTL recognize peptide fragments of cellular or viral proteins bound in the anti- 
gen-presenting groove of MHC class 1 molecules (4-8). In several 
animal models MHC class I binding peptides can induce protective 
CTL-mediated immunity against certain viruses (reviewed in  Ref. 
1). Therefore prediction of potential CTL epitopes has important 
implications for preventive andor therapeutic applications in hu- 
man diseases. 
Although many factors influencing MHC class I-restricted CTL 
responses to peptides have been elucidated, it is still not clear why 
only a few peptides are  selected  for ecognition by CTL despite the 
presence of other putative antigenic peptides within the same Ag. 
One important parameter appears to  be the  binding affinity of the 
peptide. In a large  group of peptides binding with high and inter- 
mediate affinity to  MHC class I molecules in mouse (9) and human 
(10, 11) most, but not all, peptides were immunogenic. Peptides 
binding with lower affinity to MHC class I may form less stable 
MHC-peptide complexes leading to decreased immunogenicity 
(10). Indeed, in the MHC class I-restricted response to OVA, the 
dominance and subdominance of two epitopes was not determined 
by a difference in T cell precursor frequency but was due to a 
difference in binding affinity and dissociation rate between both 
epitopes (12). Likewise the immunogenicity of at least some pep- 
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tides binding to MHC-class 11 was determined by their ability to 
stabilize the class I1 molecule in SDS-containing solutions, which 
correlated with the dissociation rate of the peptide (13). 
The binding affinity of peptides to MHC molecules at equilib- 
rium is the result of the continued association and dissociation of 
the trimolecular complex of peptide, MHC class I molecule, and 
/32m.3 The dissociation rate of peptides bound to MHC  class I is 
influenced neither by the presence of competing peptides (14) nor 
by the concentration of the competing peptides (15). On the other 
hand, the amount of free MHC peptide binding sites is influenced 
and limited by the dissociation rate of previously bound peptide 
(15). Thus a peptide with a low dissociation rate will, once bound, 
probably form a stable MHC-peptide complex in the endoplasmic 
reticulum, be transported to the cell surface, and persist there for a 
time sufficient to allow T cell recognition. 
To support this hypothesis we have determined the dissociation 
rate of a group  of  MHC  class I-binding peptides, focusing on the 
correlation between peptide binding affinity and immunogenicity 
on the one hand and between the dissociation rate of peptide from 
MHC class I molecules on the other hand. Immunogenicity ap- 
pears to correlate better with  the dissociation rate than with peptide 
binding affinity. 
Materials and  Methods 
Cell lines 
The EBV-transformed B cell line JY (HLA type: A*0201, B7, Cw7, DR4, 
DRw6, Dhu2)  was cultured in complete culture medium consisting of 
RPMI 1640 Dutch modification (Life Technologies, Paisley, Scotland) 
supplemented with 10% FCS, antibiotics (100 IU/ml penicillin (Brocades 
Pharma, Leiderdorp, The Netherlands) and IO0 pg/ml kanamycin (Sigma 
Abbreviations used in this paper: HBV, hepatitis B virus;  HCV, hepatitis C virus; 
HPVI 6. human papillomavirus type 16; HPVl1, human papillomavirus type 1 1; 
HTLVl, human T cell lymphotropic virus type 1 ; E6 and €7, early region 6- and 
structural region 3 and 4; LMP2, latent membrane protein 2; Pzm, human Pr-  
7-encoded proteins; pol, polymerase; NP, nucleoprotein; NS3 and NS4, non- 
microglobulin; IC, 50% inhibitory concentration; DT5,, time required for 50% 
of the molecules to decay; HBVc18-27, hepatitis B virus core peptide amino 
acids 18 to 27; FL, fluorescein; MF, mean  fluorescence. 
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Chemical Co., St. Louis, MO)), and 20 p M  2-ME (Merck, Darmstadt, 
Germany)  at 37°C in humidified air  containing 5% CO,. 
Jurkat A*0201Kh cells are stable transfectants of the human T cell leu- 
kemia line, Jurkat, which express the product of the HLA-A*0201Kh chi- 
meric gene (16). They are cultured in complete culture medium in the 
presence of 200  pg/ml G41 8 sulfate. 
Peptides 
Peptides were synthesized by solid phase strategies on  an automated mul- 
tiple peptide synthesizer (Abimed AMS 422, Langenfeld, Germany) using 
Fmoc chemistry. Peptides were analyzed by reverse phase HPLC, dis- 
solved in 20 pl of DMSO, diluted in 0.9% NaCl to a peptide concentration 
of 5 mg/ml, and stored at -20°C before usage. 
Fluorescein (FL)-labeled peptides as used in the competition-based 
HLA class 1 binding  assay  were  synthesized,  labeled,  and  characterized 
as described earlier (17). The sequence of the reference peptide used 
for HLA-A*0201 was FLPSDYFPSV (18, 19) wherein we substituted 
the tyrosine with a cysteine to tag a fluorescein group to the peptide: 
FLPSDC(FL)  FPSV  (17). 
Transgenic mice 
HLA-A*0201Kh transgenic mice were kindly provided by Dr. L. Sherman 
(Scripps Laboratories, San Diego, CA, through animal distributor Harlan 
Sprague-Dawley, Inc., Indianapolis, IN). Mice were held under clean con- 
ventional conditions. The transgenic mice express  the product of the HLA- 
A*0201Kh chimeric gene in which the a3 domain of the heavy chain is 
replaced by the corresponding murine H-2 Kh domain while leaving the 
HLA-A*0201 al and a 2  domains unaffected (16). This allows the murine 
CD8 molecule on the murine CD8+  T cells to interact with the syngeneic 
a3 domain of the hybrid MHC class I molecule. 
In vivo immunizations and murine T cell cultures 
Groups of three to six HLA-A*0201Kh transgenic mice were injected S.C. 
in the base of the tail with 100 pg of peptide emulsified in IFA in the 
presence of  140 pg of the H-2 I-Ah-restricted HBV core antigen-derived T 
helper epitope (128-140; sequence TPPAYRPPNAPIL) (20). After 11 
days, mice were killed and spleen cells (30 X IO6 cells in 10 ml) were 
restimulated in vitro with syngeneic-irradiated LPS-stimulated B cell lym- 
phoblasts (ratio 3:1), and I pg/ml  peptide in complete culture medium in 
T25 flasks (Falcon; Becton Dickinson, Franklin Lakes, NJ). At day 6 of 
culture, the cytotoxicity of these bulks was tested in a standard 5-h "Cr 
release assay. 
-5 Cr cytotoxicity assay 
CTL activity was measured in a standard chromium release assay as  de- 
scribed previously (21). Target cells were sensitized with 10 pg/ml peptide 
for 30 min at 37°C. Target  cells were added to various numbers of effector 
cells in a final volume of 100 p1 of complete culture medium in 96-well 
U-bottom microtiter plates. After 5 h of incubation at 37"C, supernatants 
were harvested. The mean percentage specific lysis of triplicate wells was 
calculated as follows: 
Experimental release - spontaneous release 
Maximal release - spontaneous release % specific lysis = 
The percentage of specific lysis is expressed in LU,d106 cells, in which 1 
LU,, corresponds to the number of effector cells required to induce 30% 
"Cr release from 2000 Jurkat A *0201/Kh target cells during  a 5-h assay, 
Peptide "stripping" by mild acid treatment 
JY cells were washed twice with PBS and then put to rest on ice for 5 min. 
Ten million cells were then treated for  90 s with 2 ml ice-cold citric acid- 
Na,HPO,  buffer (a mixture of an  equal volume of 0.263 M citric acid and 
0.123 M Na,HPO,), pH 3.2 (17, 22). Immediately thereafter the eluted 
cells were buffered with cold Iscove's modified Dulbecco's medium 
(IMDM), washed with IMDM. and resuspended at 1OhceIls in IMDM with 
1 pg/ml P2m (Sigma Chemical). 
Competition-based HLA class I peptide-binding assay 
Peptides were tested for their binding affinity using the previously de- 
scribed peptide-binding assay (17).  Briefly,  cells were stripped (see above) 
but resuspended at 7 X 10' cells/ml in IMDM + 1.5 pg/ml &m. A FL- 
labeled reference peptide, 25 p1 (end concentration, 150 nM), was incu- 
bated with 25 p1 of  competitor  peptide (different end concentrations) in a 
96-well V-bottom plate (Costar, Cambridge, MA). One hundred microliters 
x 100 
of mild acid-treated JY cells were added to these wells. The mixture was 
incubated for 24 h at 4"C, washed twice with PBS containing 1% BSA 
(PBAl%), resuspended in PBAl% containing 0.5% paraformaldehyde, and 
analyzed by FACScan (Becton Dickinson, Etten-Leur, The Netherlands). 
The mean fluorescence (MF) value obtained in the wells without com- 
petitor peptide was regarded as maximal binding and equated to 0% inhi- 
bition; the MF obtained from the wells without reference peptide was 
equated to 100% inhibition. Percentage inhibition of binding was calcu- 
lated using the following formula: 
( 1  - (MF 150 nM reference and competitor peptide - MF no reference pep- 
tide) + (MF 150 nM reference peptide - MF no reference peptide)) X 1 0 0 %  
The relative binding affinity  of the peptide is expressed as peptide con- 
centration needed to inhibit 50% of the binding of the reference peptide 
Affinity is categorized as follows: high IC,, < 5 pM, intermediate 
>5 pM IC,, < 15 pM, or low IC,, > 15 pM. Peptide HIV-lpol-468 
bound not with high (17) but with intermediate binding affinity. 
Measurement of MHC-peptide complex stability at  37OC 
JY cells at  a concentration of 1 to 2 million cells/ml were incubated with 
10~-' M  emetine (Sigma Chemical)  for 1 h  at 37°C to stop protein synthesis 
and thus the emergence of de novo synthesized class I molecules at the cell 
surface (22).  Cells were washed twice with PBS and peptide stripped (see 
above). One million cells were added to 200 pg of peptide in  1 ml and 
incubated for 1 h  at room temperature. Cells were washed twice with ice- 
cold IMDM and resuspended in 1 ml IMDM. Subsequently, the cells were 
incubated for 0, 2,4, and 6 h at 37°C and thereafter stained with BB7.2, an 
HLA-A2 conformation-specific mAb (23), and GaMEITC. Thereafter the 
cells were fixed by resuspension in PBAI% containing 0.5% paraformal- 
dehyde.  Cells were analyzed by FACScan. The fluorescence index (FI) was 
calculated as FI= (mean fluorescence sample - mean fluorescence back- 
ground) + mean fluorescence background (without peptide). Samples were 
tested in duplicate and the variation between both samples was always less 
that 10%. 
The percentage of residual HLA-A2 molecules was calculated by equat- 
ing for  each peptide, the FI o f t  = 0 to 100% and then using the formula: 
% remaining = (FI, = ,1 + FI, ~ o) X 100%. Because the dissociation of 
peptides from  MHC is a linear process, the stability of the peptide-MHC 
complexes was measured as the time required for 50% of the molecules to 
decay (DT,,). We have used t = 2  h at 37°C as starting point for the reason 
that from this time point only the DTso are determined from peptides that 
are able to form stable peptide-MHC complexes. 
Statistics 
Using Fisher's test for 2 by 2 tables (Fisher's exact two-tailed test), the 
dissociation rate (DT,,) of peptides at  37°C was correlated to the immu- 
nogenicity of the peptides. Binding affinity could not be correlated to im- 
munogenicity using a 2 test due to the relatively small number of peptides. 
Therefore we compared high affinity binding peptides with low affinity 
binding peptides to establish the strongest correlation between affinity and 
immunogenicity using Fisher's test for  2 by 2 tables. 
Results 
Stability of MHC class I molecules complexed with HBV- or 
HPV76-derived peptides of known binding affinity and 
immunogenicity in HLA-A*0201/@ transgenic mice 
To study the relation between dissociation of peptides bound to 
MHC  class I molecules and their ability to induce a  CTL response, 
we used nine peptides derived from HBV polymerase (pol) and 
eight peptides of HPV16 of which the relative binding affinity and 
immunogenicity in HLA-A*0201/Kb transgenic mice was reported 
previously (10, 1 1,24). To show that all 17 peptides indeed bound 
to HLA-A*0201, we tested their affinity in a previously described 
competition-based HLA-class I binding assay (17). HBVpol-635, 
HPV16E7-11, and HPV16E7-86 bound with relatively high affin- 
ity ( ( 5  pM). Fourteen peptides bound with intermediate (between 
5 and 15 pM) or low affinity (> 15 p M  (Table I). Peptide binding 
affinities measured and classification of the peptide binding affinity 
into high, intermediate, and low are comparable to the affinities 
and classifications of Sette  et al. (10) and Kast et al. (24). 
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7-1 5 AMFQDPQER 1,818 17.5 - NS 
26-34 LQTTlHDll 3,157  20.5 - NS 
Peptide origin, position of first and last amino acid, and the amino acid sequence  and binding affinity as described previously (10, 24) 
Affinity was  measured as described recently (1 7). ICs, represents  the  amount of peptide required for 50% inhibition of binding  of the fluorescein-labeled reference 
Immunogenicity of the peptide was determined by injection of peptide doses of 10- to 100-fold in excess of the amount required to elicit optimal CTL responses 
peptide to HLA-A*0201. 
emulsified in IFA  together with an equimolar amount of I-Ab T-helper epitope (10,  11): -, nonimmunogenic; t, immunogenic. 
dDTsO is given starting from t = 2 h at 37°C. NS = nonstable: <lo% of HLA molecules were detectable after a 2-h incubation at 37°C. 
Table II. Comparison ofpeptide binding afinity, dissociation rate, 
and immunogenicity of HBV- and HPVl6-derived peptides 
Peptide Binding 
Dissociation Rate (DT,) 
Affinity 2 3  h < 3  tl Immunogenicity 
High  3 0 Immunogenic 
Intermediate 3 0 Immunogenic 
Low 0 0 Immunogenic 
0 0 Nonimmunogenic 
4  Nonimmunogenic 
7  Nonimmunogenic 
0 
0 
Subsequently with  the  use  of a conformation-specific anti-HLA-A2 
Ab, the amount of residual HLA-A*0201 peptide complexes was 
monitored  in  time. The loss of peptide-stabilized  HLA-A*0201 mol- 
ecules at the cell surface represents the dissociation of the peptide 
from the class I molecule to which  the  peptide  is  bound. The stability 
is  then  presented  by the time  required for 50% of  the  molecules to 
decay (DT,,).  All three  high  affinity  binding  peptides  and  three of the 
intermediate affinity binding peptides, HBVpol-996, HBVpoZ-1076, 
and HPV16E7-82 showed a DT,, 2 3 h (Table I). The four other 
peptides of intermediate affinity,  HBVpoZ- 1344, I"V 16E6- 18, 
HpV16E6-52, and HPV16E7-7 showed a DT,, between 1 and 2 h 
(Table I). The low affinity binding peptides  showed a DT,,  of 1 h or 
less. In Table II we show a comparison  between  the  dissociation  rate, 
binding affinity, and immunogenicity of these peptides. All high  af- 
finity  binding  peptides form stable MHC-peptide complexes and are 
immunogenic, whereas the group of peptides of intermediate affinity 
contains either peptides  that are immunogenic and form stable MHC- 
peptide complexes or are nonimmunogenic and do not form stable 
MHC-peptide complexes as shown by their high dissociation rates 
(Table II). 
Stability of MHC class I molecules complexed with known 
human CTL epitopes 
Seventeen HLA-A*0201-binding peptides earlier reported to be 
immunogenic (e.g. found as CTL  epitope or capable of inducing a 
primary response) (20,24-36) were tested for their binding affinity 
to HLA-A*0201. Eight peptides bound with high affinity, seven 
peptides bound with intermediate affinity, and  two peptides bound 
with low affinity (Table 111). The dissociation rates were deter- 
mined and virtually all peptides showed a DT,, ? 4 h, except for 
the peptides HPVl1 E7-4 and HIV-lpol-267. The HPVllE7-4 and 
HIV-lpol-267 CTL epitopes, both found by primary CTL induc- 
tion using synthetic peptide or cells expressing extremely high 
amounts of Ag, dissociated faster (DT,, 5 2 h (Table 111). Inter- 
estingly, the sequence of the HCVlcore-13 1 peptide [ADLMGYI 
PLV] does not correspond precisely to the HLA-A*0201 motif. 
The HCVcore-132 peptide that lacks the N-terminal alanine 
(DLMGYIPLV) fits better to the HLA-A*0201 motif. This is  also 
reflected in the higher affinity of this shorter peptide (ICso = 5.0 
pM), but the peptide dissociates more quickly (Fig. 1) than the 
HCVcore-131 peptide. 
Immunogenicity is correlated with the dissociation rate 
A significant correlation exists between the immunogenicity of a 
peptide and the dissociation rate. Of the investigated known HLA- 
A*0201-restricted immunogenic peptides, 21 of 23 showed a 
DT,, 2 3 h, while none of the 1 1  nonimmunogenic peptides 
showed a DT,, 2 3 h ( p  = 0.0000003, Table IV). This correlation 
is closer than that between peptide binding affinity and immuno- 
genicity ( p  = 0.0005, Table  IV) and confirms the trend visible in 
Table 11. When the correlation between immunogenicity and dis- 
sociation rate was investigated for peptides binding with interme- 
diate or low affinity, this was still better correlated (p = 0.00007, 
Table  V) to immunogenicity than affinity ( p  = 0.04). This implies 
that peptides that are processed, transported to the endoplasmic 
reticulum, and are able to form stable MHC-peptide complexes are 
likely to be CTL epitopes. 
Immunogenicity in HLA-A*0201/@ transgenic mice of HIV- 
1-derived peptides with known affinity and dissociation rate 
To assess the in vivo immunogenicity of peptides of which the 
binding affinity and the dissociation rate was measured, HLA- 
A*0201/Kb transgenic mice were vaccinated with two control 
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Table 111. Stability of HLA-A*0201  complexed  with  known CTL epitopes 
First aa Affinity Stability 
Peptide Position Sequence (ICs, (PM)) (DT,,) Immunogenicity 
HCVl  core 131  ADLMGYIPLVa 50.0b >4 h' RCd 
HCVl  core 178 LLALLSCLTV 7.5 >4 h RC 
HCVl  NS3 1406  KLVALCINAV 5 .O 4 h  RC 
HCVl  NS4 1789 SLMAFTAAV 1.5  =.4 h RC 
HBV surface 335 WLSLLVPFV 1 .o >4 h RC 
HBV surface 348 GLSPTVWLSV 2.0 >4 h RC 
EBV LMP2 426 CLGCLLTMV 2.5 4 h  PR1 
HTLVl tax 11 LLFGYPVYV 0.8 >4 h RC 
H P V l l  E7 4 RLVTLKDIV 52.0 2 h  PR2 
INF B NP 85 KLGEFYNQMM 5.5 >4 h CTL 
INF A matrix 58 GILGFVFTL 0.6 >4 h CTL 
HIV-1 Gag 76 SLYNTVATL 1.5 >4 h CTL 
HIV-1 Pol 468 ILKEPVHGV 8.0 >4 h CTL 
pmel17/gpl00 11 I YLEPCPVTA 8.5 4 h  CTL 
pmell7/gp100 [21 LLDGTATLRL 5.5 4 h  CTL 
Tyrosinase 369  YMNGTMSQV 4.5 >4 h CTL 
HIV-1 POI 267 VLDVGDAYFSV 7.0 NS PR3 
' I  Peptide origin, position of first amlno acid, and  the amino acid sequence  of  the different HLA-A*0201-restricted CTL epitopes are given (20, 25-36). 
Bmding affinity was  measured as described recently ( 1  7). ICso represents  the amount of peptide required for 50% inhibition of binding of the fluorescein-labeled 
DT, is given starting from t = 2 h at 37OC. NS = nonstable, <lo% of HLA molecules were detectable after a 2-h incubation at 37°C. 
reference peptide to HLA-A*0201 
authors  used similar protocols. CTL, peptides  were  used to identify the  epitopes recognized by CTL that  were obtained from patients. PR1, CTL were primed in vitro 
dRC, recall experiment wherein CTL already primed by viral infection of the patient in vivo were  boosted in vitro with peptide to detect  the  precise epitope. All 
with an autologous EBV-transformed B cell  line and then cloned, peptides  were  used to map the epitope recognized. PR2, CTL were induced in vitro using repeated 
stimulation with recombinant vaccinia virus-HPV11 E7-infected B cells. PR3, CTL were induced in vitro using repetitive stimulation with peptide pulsed APCs. 
FIGURE 1, Binding affinity and dissociation rate of 
the HCVl core-1 31 peptide  and the shorter variant 
without the N-terminal alanine. The binding affinity 2 8o 
(left) and the dissociation rate (right)  of the HLA- 2 
A*0201-restricted CTL epitope HCVlcore-131 (0; C 
ADLMGYIPLV) (25) and shorter variant (0; DLM- .s 60" 
CYIPLV), which corresponds more precisely to the 
HLA-A*0201 motif, was tested (see Materials and 
Methods). The mean inhibition  of the reference pep- 
tide at each concentration of competitor peptide, ob- 
tained in two independent experiments, is shown at 
the left. The right figure shows the percentage of re- 
sidual peptide-MHC molecules for both peptides at 
each time  point (mean of two independent experi- 
ments).  The percentage of molecules present  at t = 2 
h was  set to  100%. The lines are the result of linear 
regression  analysis. 
Cl00- 
0 20 40 M) 80 100 2 4 6 
competitor  pe tide UM time (hours) 
Table IV. Statistical analysis of the dissociation rate (DT,a) or 
binding affinity vs immunogenicity of HLA-At0207-binding  peptides 
Immunogenic  Noni i  
DT, 2 3 h 21 0 
DT, < 3 h 2 11 
High affinity 11 0 
Intermediate affinity 10 4 
Low affinity 2 7 
p = 0.0000003a 
D = O.OOOSb 
Fisher's two-tailed exact  test  for 2 by 2 tables. 
by comparison of the high affinity-binding peptides with the low affinity-binding 
"The relation between binding affinity and immunogenicity was determined 
peptides, using fisher's two-tailed exact  test  for 2 by 2 tables. 
peptides (HPV16E7-86 and HBVcore-18; FLPSDDF'PSV) and 
four HIV-1-derived peptides (Table VI). The derivation of these 
transgenic mice (16) and their use to analyze in vivo immunoge- 
nicity have been described previously (10, I I). The HIV-lpol-468; 
(ILKEPVHGV) is a CTL epitope and binds with intermediate af- 
Table V. Statistical analysis of dissociation  rate (DT,,,j or binding 
affinity vs immunogenicity of peptides binding with  intermediate or 
l ow  affinity  to HLA-A*0201 
Immunogenic Nonimmunogenic 
DT, 2 3 h 10 0 
DTSo < 3 h 2 11 
Intermediate  affinity 10 4 
Low  affinity 2 7 
p = 0.00007a 
p = 0.04" 
a Fisher's two-tailed exact  test  for 2  by  2 tables. 
finity. The HIV-lpoE-267;(VLDVGDAYFSV) peptide was found 
to be immunogenic in a human primary CTL induction after re- 
petitive stimulations with relatively high doses of peptide (20). To 
test the predictive value of the in vitro-measured MHC-peptide 
complex stability, we determined the binding affinity and dissoci- 
ation rate of the two other HIV-lpol peptides (HIV-lpol-343: YM 
DDLYVGSDL and HIV-lpol-576: LLWKGEGAV) (Table VI). 
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Table VI. Immunogenicity of HIV-1-derived peptides with  known dissociation rate  tested in HLA-A*020?/Kb transgenic mice 
Affinity 
Sequence + Origin 
FLPSDDFPSV HBVcore-1  8a 
TLClVCPl HPVl65'-86 
Stability 






0.7 >4 h 183 (70-400) 3/3  
7 .O NS <2 Of 7 
8.0 l h  <2 0/3 
6.0 >4 h 84 (67-1 00) 2/3 
8.0 >4 h 56 (1  7-1 00) 516 
>4 h' 53 (25-71)d 3/3e 
VLDVCDAYFSV HIV-lpol-267 
YMDDLYVGSDL  HIV-1 POL343 
LLWKCEGAV HIV-lpol-576 
ILKEPVHGV HIV-lp0/-468 
a Peptide amino acid sequence, protein, and the position of the  first amino acid of the different HLA-A*0201 binding potential CTL epitopes  are  given. 
'Average binding affinity was measured as described recently (1 7). IC, represents the amount of peptide required for 50% inhibition of binding of the fluorescein- 
' DT, is given starting from t = 2 h at 37% NS = nonstable: < lo% of HLA molecules were  detectable  after a 2-h incubation at  37°C. 
e Number of mice that mounted a peptide-specific CTL  response  per total mice vaccinated. 
labeled reference peptide to HLA-A*0201, 
Average  of all mice and  range of observed  responses. 
FIGURE 2. Peptide-specific cytotoxicity induced 
by vaccination of HLA-A'0201 Kb transgenic mice. 
A representative experiment in  which HLA- 
A*0201Kb transgenic mice were vaccinated with 
indicated peptide displaying a low dissociation rate 
(A, 6, and E )  or high dissociation rate (C and D) in 
combination with an HBV core-encoded T helper 
epitope in F A  (see Materials and Methods). Bulk 
CTL cultures derived from spleen cell of  these mice 
were  tested for peptide specificity in cytotoxicity as- 
says on Jurkat A*0201 Kb target cells pulsed with (0) 
or without (0) specific peptide. Shown is the  mean 
specific  lysis  of bulk CTL from three to six animals 
with indicated standard deviation. Specific lysis is 
depicted at an E:T ratio varying from 1.5 to 100. 
701 A PLPSDDPPSV 
60 ,* No peptide 
0- 




0 20 40 60 00 1 0 0  
0 20 40 60 80 100 
E:T ratio 
0 ILKEPVHGV 
No peptide I 
20 l!c!z 1  n
- 
0 20 40 60 00 1 0 0  
YMDDLYVGSDL 




0 20 40 60 00 100 
Both peptides were detected when the highly conserved regions of 
HIV-lpol were screened for amino acid sequences that contained 
two anchors for binding to HLA-A*0201, as described previously 
(20). We vaccinated groups of mice with all the peptides. Bulk 
CTL derived from mice vaccinated with the  control peptides spe- 
cifically lysed peptide-sensitized Jurkat A*020i/Kb cells (Fig. 2; 
Table VI). As expected, all peptides with a low dissociation rate 
mounted a CTL response (Fig. 2; Table VI), whereas the two pep- 
tides with high relative dissociation rates did not induce a CTL 
response (Fig. 2; Table VI). Thus, the immunogenicity of these 
peptides was perfectly predicted by their dissociation rates. 
Discussion 
The results of this study show that peptide-induced MHC stability 
and immunogenicity of the  peptide are strongly correlated. We find 
a closer correlation between the dissociation rate of a peptide and 
immunogenicity ( p  = 0.0000003) than between binding affinity 
and immunogenicity ( p  = 0.0005). The better correlation is gained 
in the group of peptides that bind with intermediate or low affinity. 
Immunogenic peptides in this group are characterized by a low 
dissociation rate, meaning that they induce stable MHC-peptide 
complexes. 
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To study the impact of a stable MHC-peptide complex on its 
immunogenicity, we tested 34 peptides with known immunoge- 
nicity, determined either  in HLA-A*0201/Kb transgenic mice 
andlor in humans, for their capacity to form stable MHC class 
I-peptide complexes at 37°C. All peptides with a high af&inity for 
the MHC class I molecule have been reported to be immunogenic 
(IO, 11) and the dissociation rates of these  peptides were found to 
be low, as shown by a DT,, 2 4 h. Furthermore, low  or interme- 
diate affinity MHC-binding peptides with a low dissociation rate 
were immunogenic, whereas those with a high dissociation rate 
were not. Moreover, selection of potential CTL epitopes based on 
binding affinity alone would have favored  the HCVlcore-132 
(DLMGYIPLV) peptide, which corresponds more precisely to the 
HLA-A*0201 binding motif, over the HCVlcore-131 (ADLM 
GYIPLV) peptide. The HCVlcore-131 peptide, however, would 
be selected by its superior capacity to form stable MHC-peptide 
complexes, and this peptide was reported to be more immunogenic 
(25, 37) (A. Cerny, personal communication). 
Therefore the dissociation rate can be used to predict  the im- 
munogenicity of candidate  CTL epitopes. As shown in  Table V, 
the dissociation rate of peptides binding with intermediate &nity 
correlated well with their immunogenicity, indicating that this is an 
important parameter for the prediction of their immunogenicity. 
Indeed peptides that formed  stable MHC-peptide complexes were 
immunogenic  in HLA-A*0201/Kb mice (Table VI), whereas pep- 
tides displaying high dissociation rates were not, although immu- 
nizing doses were used that were 10- to 100-fold in  excess  of what 
is required to elicit optimal CTL responses in a system for evoking 
CTL, in which help is not limiting (10). 
The influence of temperature on binding alXnity (14, 38) might 
explain why some peptides binding with intermediate &nity are 
nonimmunogenic. For technical reasons binding affinity is mea- 
sured at nonphysiologic temperatures (5 23°C) when the class I 
molecule is probably in an “open” conformation. The  peptide will 
interact with sites at the peptide binding groove resulting in a con- 
formational change of the molecule and a tight fit for the anchor 
residues. Without this conformational change a peptide will dis- 
sociate at 37°C (14). Still a substantial group of immunogenic 
peptides exists that bind with intermediate or low affinity. These 
peptides can differ from the group of peptides that bind with high 
affinity by either a lower association rate or a higher dissociation 
rate. Peptides that display a higher dissociation rate  are probably 
nonimmunogenic, whereas those peptides with lower dissociation 
rates will be immunogenic. 
A DT,, 5 3 h as a cutoff point is  based  on the results of the first 
two series of immunogenic and nonimmunogenic peptides tested 
(Table I). From all the known CTL epitopes (Table III), three 
epitopes were found by primary CTL induction in vitro. All the 
others were found by culturing  CTL obtained from patients. Two 
of these  three  immunogenic  peptides  displayed a DT,, < 3 h and 
seem to form an exception. The HIV-lpol-267 and HPVl1E7-4 
peptides formed unstable MHC-peptide complexes but were found 
to be immunogenic in a primary CTL response. Although both 
primary responses were induced in different ways, they were the 
result of repetitive stimulation with either exogenously added pep- 
tide or recombinant vaccinia-infected cells overexpressing the 
epitope. Vaccinia virus shuts  down host protein synthesis and rep- 
licates in  the  cytoplasm.  Therefore the high level of protein ex- 
pressed by the recombinant vaccinia construct leads to high levels 
of peptide derived from this protein that will be presented in the 
class I molecules. In the case of nonlytic viruses, on the other hand, 
a relatively low amount of virus proteins must compete with host 
proteins for generation and presentation of peptides, thus, only 
peptides with low dissociation rates will be presented at the cell 
surface. A good  example for this is the third epitope found by in 
vitro primary induction, the EBV LMP2  epitope (27). CTL were 
obtained by culturing PBMC with autologous EBV-transformed B 
cells. In this case,  the peptides generated from EBV proteins must 
compete with those from host-derived proteins and indeed the pep- 
tide found shows a low dissociation rate. The HPV16E6-18 pep- 
tide earlier reported to be processed (39) was eluted from recom- 
binant vaccinia-infected cells. This peptide, however, is not 
immunogenic in the HLA-A*0201/Kb mice and showed a high 
dissociation rate. Furthermore, other  HPVl6-derived peptides that 
displayed higher dissociation rates and are nonimmunogenic in the 
HLA-A*0201/Kb mice, are occasionally able to induce primary T 
cell responses but only after repetitive stimulation with high doses 
of exogenously added peptide (1 1). Thus, it is possible for T cells 
to react to unstable MHC-peptide complexes in such a way that 
they recognize the endogenously processed peptide when this par- 
ticular epitope  is expressed at high levels (20, 29), but in the case 
of tumor Ags and nonlytic viruses the in vivo relevance of such 
peptides is uncertain on the basis of our results. 
We show that the in vitro dissociation rate is related to the 
immunogenicity of a peptide. Apparently this predicts whether a 
peptide can persist at the cell surface for a time sufficient to allow 
the induction of a CTL response. Unfortunately, it does not predict 
whether a peptide will be endogenously processed and presented in 
the context of MHC class I. This is dependent on the presence of 
enzymatic cleavage sites in the flanking sequences of the peptide 
as shown by Ossendorp et aL4 They found that a single amino acid 
difference within a viral epitope caused the destruction of the 
epitope derived from a related virus due to specific proteasome 
cleavage. Both peptides showed the same binding affinity and both 
were immunogenic when injected as a synthetic peptide. Also of 
influence is the transport of peptides to the endoplasmic reticulum 
by TAP although human TAP molecules are reported hardly to 
select for peptides (40). There might aIso be a relation between the 
amount of peptides created and immunogenicity; it  is conceivable 
that due to a limited amount of protein in the cytoplasm, not 
enough peptides are presented at the cell surface to induce a CTL 
response. If the rules for processing of peptides are more precisely 
known we will be able to even more accurately  predict  which  protein- 
derived  peptides  will be in vivo  relevant CTL epitopes and might be 
selected for use in peptide-based  immunotherapeutic  vaccines. 
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